Full Text View
Tabular View
No Study Results Posted
Related Studies
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
This study has been completed.
Study NCT00528450   Information provided by Memorial Sloan-Kettering Cancer Center

First Received on September 10, 2007.   Last Updated on March 15, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Additional conditions recognized in this trial
Leukemia, Promyelocytic, Acute
More general conditions related to this trial
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
arsenic trioxide
idarubicin
tretinoin
More general drug interventions related to this trial
Antibiotics, Antineoplastic
Antineoplastic Agents
Dermatologic Agents
Keratolytic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Cephalon


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services